Companion Diagnostics Oncology Market Forecast: NGS Scaling, Liquid...

toegevoegd een audio Other

2026-03-06 09:03:01 -

Companion Diagnostics Oncology Market Forecast: NGS Scaling, Liquid Biopsy Growth, and Tumor-Agnostic Testing (2026–2034)

The companion diagnostics (CDx) oncology market is a pivotal enabler of precision cancer care—matching targeted therapies to patients most likely to benefit through biomarker-defined decisions. CDx detect molecular, protein, or genomic features tied to a drug’s efficacy, safety, or optimal use. In oncology, they guide therapy selection and switching as resistance emerges across...

0 Reacties 0 aandelen 58 Views